Palvella Therapeutics, Inc. (PVLA) Equity Ratio (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Equity Ratio for 12 consecutive years, with 4.26 as the latest value for Q3 2024.
- On a quarterly basis, Equity Ratio fell 928.86% to 4.26 in Q3 2024 year-over-year; TTM through Sep 2024 was 4.26, a 928.86% decrease, with the full-year FY2023 number at 9.87, down 904.82% from a year prior.
- Equity Ratio was 4.26 for Q3 2024 at Palvella Therapeutics, down from 3.23 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 3.2 in Q3 2022 to a low of 9.87 in Q4 2023.
- A 5-year average of 0.69 and a median of 0.33 in 2021 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: soared 876.11% in 2022, then crashed 1486.82% in 2024.
- Palvella Therapeutics' Equity Ratio stood at 0.3 in 2020, then increased by 11.86% to 0.33 in 2021, then crashed by 397.12% to 0.98 in 2022, then plummeted by 904.82% to 9.87 in 2023, then skyrocketed by 56.84% to 4.26 in 2024.
- Per Business Quant, the three most recent readings for PVLA's Equity Ratio are 4.26 (Q3 2024), 3.23 (Q2 2024), and 2.61 (Q1 2024).